STOCKS TELEGRAPH

Author: Shimrez Hyder

  • So-Young International Inc. (SY) Stock Surges Following Disclosure of Financial Reports for Q2 2021

    So-Young International Inc. (SY) Stock Surges Following Disclosure of Financial Reports for Q2 2021

    So-Young International Inc. (SY) stock prices were up by 2.77% as of the market closing on September 9th, 2021. This brought the price per share up to USD$5.19 at the end of the trading day. Subsequent premarket fluctuations saw the stock increase by 15.22%, bringing it up to USD$5.98.

    Expansion of Customer Base

    The second quarter of fiscal 2020 saw SY stock report the continued growth of its customer base. This was facilitated by the insights gained by the company’s platform over the past several years in regard to popular trends and consumer behaviors.  Average mobile MAUs were up to 10 million for Q2 2021, an increase of 47.5% as compared to the prior-year quarter. the company experienced a massive surge in demand for non-surgical categories. These categories made up 70% of total online reservation orders during the quarter. Accordingly, the company implemented a series of operational measures to further consolidate its potential. The company is forecasting rapid growth in the Chinese medical aesthetics industry.

    Continued Growth

    The company’s strong financial results indicated a substantially improved profitability. Strong user growth and the consolidation of the company’s brand name resulted in a growth of providers on its platform. The number of paying medical service providers on SY stock’s platform was up by 31.2% as compared to the prior-year quarter, with the 2021 quarter reporting a total of 4,899. The company also made significant strides in developing more popular categories, such as premium dental services.

    SY Stock’s Liquidity Position

    SY stock reported a solid liquidity position as of the end of the second quarter of fiscal 2021. The company had cash and cash equivalents, restricted cash and term deposits, term deposits, and short-term investments in the amount of USD$350.4 million as of June 30th, 2021. This is comparable to the USD$415.60 million reported as of December 31st, 2020.

    SY Stock’s Revenue Report

    Total revenues for the second quarter of fiscal 2021 came out to USD$70 million. This is a 37.7% increase from the numbers reported for the prior-year quarter. the year over year difference was largely driven by an increase in average revenue per paying the medical service provider.

    Future Outlook for SY Stock

    SY stock reported a promising quarter, as evidenced by the success of its financial reports for Q2 2021. The company is keen to allocate resources towards maintaining the momentum generated over the first half of fiscal 2021. Investors are hopeful that management will be able to usher inconsistent and organic growth over the long term.

  • Inmatics NV (IMTX) Stock Trends Higher as Momentum from Q2 2021 Financial Reports Continues

    Inmatics NV (IMTX) Stock Trends Higher as Momentum from Q2 2021 Financial Reports Continues

    Inmatics NV (IMTX) stock prices were up by 2.25% as of the market closing on September 9th, 2021. This brought the price per share up to USD$15.46 at the end of the trading day. Subsequent premarket fluctuations saw the stock surge by 6.60%, bringing it up to USD$16.48.

    ACTengine Program Development

    The second quarter of fiscal 2021 saw IMTX stock report a significant increase in patient enrollment in its ACTengine programs. Initial results for the programs were positive in the first quarter of fiscal 2021. Following this success, the company is working towards announcing more advanced data in the second half of 2021. These data include, but are not limited to, safety, biological activity, and the assessment of anti-tumor activity for a myriad of various cancer indications.

    Clinical Trial Application

    The company is also allocating resources towards moving its second therapeutic modality towards the clinic. The entirety of the IMA401 data set is highly encouraging, with IMTX setting the stage to submit a Clinical Trial Application. The application follows collaborations with regulatory authorities and is expected for the fourth quarter of fiscal 2021. The company’s TCER pipeline is additionally consolidated by its second TCR Bispecifics program, IMA402. Preclinical proof-of-concept data for the program was recently presented.

    IMTX Stock’s Revenue Reports

    Total revenues for the second quarter of fiscal 2021 came in at USD$6.2 million, generated by revenue from collaboration agreements. This is comparable to the USD$8.2 million reported for the prior-year quarter. The end of Q2 2021 also saw IMTX stock report a solid liquidity position. Cash and cash equivalents, and other financial assets were reported in the amount of USD$229.1 million as of June 30th, 2021. This is comparable to the USD$257.5 million reported as of March 31st, 2021.

    IMTX Stock’s R&D Expenses

    Research and development costs for the 2021 quarter were reported at USD$24.1 million. This is an increase from the USD$19.7 million reported for the prior year quarter. The year over year difference was largely driven by an expansion of clinical activities for the ACTengine IMA200 series. Further consolidating the yearly difference was GMP manufacturing for the company’s TCER compound, IMA401.

    Future Outlook for IMTX Stock

    IMTX stock reported a promising quarter, the momentum of which has continued to propel the company’s trajectory of success. The company is poised to capitalize on the expanded scope of its business as it ushers in further organic and unprecedented growth. Current and potential investors are hopeful that management will be able to leverage the resources at their disposal. This is hoped to result in significant and sustained increases in shareholder value.

  • Gevo Inc. (GEVO) Stock Surges Following Letter of Intent to Collaborate with Chevron

    Gevo Inc. (GEVO) Stock Surges Following Letter of Intent to Collaborate with Chevron

    Gevo Inc. (GEVO) stock prices surged by 35.40% some time after market trading commenced on September 9th, 2021. This brought the price per share up to USD$7.84 early on in the trading day.

    GEVO Stock Partners with Chevron

    September 9th, 2021 saw GEVO stock announce a letter of intent to jointly invest in the building and operation of at least one new facility. The agreement was signed with Chevron U.S.A. These facilities will be designed to process inedible corn to produce sustainable aviation fuel. This is expected to lower the lifecycle carbon intensity of fuels used in the aviation industry. The new facilities would also produce proteins and corn oil.

    Scope of Collaboration

    The pending partnership will see GEVO stock operate its proprietary technology to produce sustainable aviation fuel and renewable blending components for motor oil. This will facilitate a reduction in lifecycle carbon intensity. As per the agreement, Chevron would be entitled to offtake roughly 150 million gallons every year to market to customers. This is in addition to the possibility of co-investing with Gevo in additional projects.

    Synergistic Partnership

    The partnering company is facilitating the provision of next-gen renewable fuels for GEVO stock’s customers. The upcoming investment will see the leveraging of the company’s unique approach to producing sustainable aviation fuel. This will complement other renewable fuels investments that the company is making as a part of its higher returns, lower carbon strategy. The collaboration will help develop the company’s capacity to produce renewable, high-performing hydrocarbons. These can be used in existing equipment and engines.

    Finalizing the Transaction

    Chevron’s leading market position will facilitate the offtaking of production from the venture. This will help to place sustainable aviation fuel with airline customers. The pending collaboration is subject to the negotiation of definitive agreements between the involved parties, as well as regulatory approval. As it stands, Chevron is currently on of the world’s leading integrated energy companies. The collaboration is set to expand the scope of both GEVO stock and its partnering company.

    Future Outlook for GEVO Stock

    The company reported a promising quarter, topped off with its recent letter of intent to collaborate with Chevron. GEVO stock is poised to capitalize on the opportunities afforded to it as a result of the pending partnership. Current and potential investors are hopeful that management will be able to leverage the resources at their disposal. This is hoped to facilitate significant and sustained increases in shareholder value.

  • Torrid Holdings Inc. (CURV) Stock Surges Following Immense Success of Financial Reports for Q2 2021

    Torrid Holdings Inc. (CURV) stock prices surged by 27.10% some time after market trading commenced on September9th 2021. This brought the price per share up to USD$23.42 early on in the trading day.

    CURV Stock’s Stellar Q2 2021

    The company reported a promising second quarter of fiscal 2021, consolidated by the successful completion of its IPO. CURV stock’s success is attributable to its focus on both fit and on delivering an unmatched customer experience. The company is aiming to be the industry leader in direct-to-consumer apparel and intimates brand for women sizes 10 to 30. Management is confident that a favorable mix of market conditions and business strategy will facilitate a continued trajectory of success.

    Net Sales Reports

    Net sales for the second quarter of fiscal 2021 were reported by CURV stock at USD$332.9 million. This is a 34% year over year increase from the USD$249.2 million reported in the prior year quarter. The second quarter of 2019 reported net sales in the amount of USD$257.4 million, representing a 29% increase in Q2 2021. The yearly increases were largely driven by the continued growth in the company’s e-Commerce business. The gains were also consolidated by improvements in store productivity trends. Comparable sales were up 30% in Q2 2021 as compared to Q2 2020.

    Gross Profit and Margin

    Gross profits for Q2 2021 were reported in the amount of USD$149.7 million. This represents an increase of 87% from the USD$80 million reported for the second quarter of fiscal 2020. Q2 2021 gross profit was 46% higher than the 102.5 million reported in the corresponding quarter in 2019. Gross margin for the 2021 quarter came in at 45%. This represents a 1,290 basis point increase from reports from Q2 2020 and a 520 basis point increase from Q2 2019. The yearly increase was largely attributable to less discounting in the 2021 quarter.

    CURV Stock’s Liquidity Position

    CURV stock reported a solid liquidity position as of the end of the second quarter of fiscal 2021. The company reported cash and cash equivalents in the amount of USD$50.5 million as of July 31st 2021. This is comparable to the USD$123 million reported as of December 31st 2020.

    Future Outlook for CURV Stock

    The company reported a stellar quarter, evidenced by the immense success of its financial reports for Q2 2021. CURV stock is poised to capitalize on the immense momentum generated, which it hopes will see it through another several successful quarters. Investors are hopeful that management will be able to usher in consistent organic growth over the long term.

  • Borqs Technologies Inc. (BRQS) Stock Trends Higher Following Signing of Binding Term Sheet with Holy Hou LLC

    Borqs Technologies Inc. (BRQS) Stock Trends Higher Following Signing of Binding Term Sheet with Holy Hou LLC

    Borqs Technologies Inc. (BRQS) stock prices were up by 1.78% shortly after market trading commenced on September 9th 2021. This brought the price per share up to USD$0.81 early on in the trading day.

    BRQS Stock Partners with Holu Hou

    September 9th 2021 saw BRQS stock announce the signing of a preliminary binding term sheet. This will see the company acquire a 51% ownership stake in Holu Hou Energy LLC. Holu Hou is an innovative solar energy and storage provider for various markets, including residential, multi-family residential, and commercial building markets. The partnering company has developed a cutting-edge energy storage system for multi-dwelling unit properties and single-dwelling residences. This makes HHE a prime candidate for collaborating with the global provider of embedded software and products for the Internet of Things.

    Scope of Smart Home Market

    BRQS stock continues to allocate resources towards its key initiative of growing its Smart Home Energy System platform. The platform caters to a US Smart Home market that is forecasted to expand to USD$62.7 billion by 2023, as per Statista projections. The global market for Smart Homes is expected to grow to USD$622 billion by 2026. The partnering company has nearly USD$150 million pf projects in its development pipeline. USD$90 million are multi-dwelling projects, while commercial projects account for more than USD$57 million.

    Synergistic Collaboration

    HHE’s energy storage system makes use of the company’s proprietary technology for sharing excess PV generation. The surplus PV is split between multiple units in a multi-dwelling unit (MDU) properties. This significantly increases the use of solar power generation, while reducing the number of batteries needed. Holu Hou is the only US company with the ability to deliver this unique micro-grid capability. It is also the first US company to open the vast MDU market to solar generation. The first landmark site in the US was the 134 unit property that is in operation in Hawaii.

    Future Outlook for BRQS Stock

    With involvement in such burgeoning markets, BRQS stock is keen to complete its transaction with Holu Hou. The company is poised to capitalize on the opportunities afforded to it as a result of the collaboration. Current and potential investors are hopeful that management will be able to leverage the resources at their disposal. This is hoped to facilitate significant and sustained increases in shareholder value.

  • Zhihu Inc. (ZH) Stock Trends Lower as Momentum Generated in Q2 2021 Fizzles

    Zhihu Inc. (ZH) Stock Trends Lower as Momentum Generated in Q2 2021 Fizzles

    Zhihu Inc. (ZH) stock prices were down by 0.27% as of the market closing on September 8th, 2021. This brought the price per share down to USD$11.08 at the end of the trading day. Subsequent premarket fluctuations saw the stock dip by 2.17%, bringing it down to USD$11.08.

    ZH Stock’s Continued Improvements

    ZH stock’s quarterly improvements were consolidated by the growth in operating and financial performance for Q2 2021. The company’s founding belief is to establish a content-centric ecosystem via a sustainable commercialization model. This is the fundamental driver behind the company’s success over the past quarters. The company is allocating resources towards maintaining the momentum generated. This includes the optimization of the company’s content structure as it refines its evaluation standards for quality content. These measures are hoped to facilitate enhancing a “sense of fulfilment” for its users.

    Facilitating Quality Content

    The producing of quality content will expand the scope of the company’s reach, facilitating broader horizons and the provision of resolutions. This is expected to strengthen users’ trust in ZH stock from its users, content creators, and its platform. It will also be a critical element in the enhancement of the company’s unique position in the market, thereby consolidating its market leadership.

    Increase in ZH Stocks MAUs

    The second quarter of fiscal 2021 saw the company’s user base continue to exhibit rapid growth. Average monthly average users were up by 46% as compared to the prior year quarter, coming in at 94.3 million for the quarter. ZH stock’s content-centric monetization reported similar growth, ushering in a 144% year over year increase in revenue for the quarter.

    Gross Margin Report

    ZH stock’s revenue structure saw healthy diversification over the course of the quarter. A higher percentage of revenue was generated from content-commerce solutions and paid memberships. Concurrently, gross margin stayed strong at 59% for Q2 2021. This is comparable to the 48% gross margin reported for the prior year quarter. This consolidated the company’s strong capability to upgrade its content infrastructure. Accordingly, the company finds itself able to continue creating long-term value for its users, business partners, and shareholders.

    Future Outlook for ZH Stock

    The company had a promising second quarter of fiscal 2021, consolidated by the continued strength of its quarterly financial reports. ZH stock is poised to capitalize on the momentum generated as it allocates resources towards the improvement of the content it provides. Current and potential investors are hopeful that management will be able to usher in consistent increases in shareholder value over the long term.

  • Gain Therapeutics Inc. (GANX) Stock Exhibits Volatility Following Announcement of Topline Data from Clinical Studies

    Gain Therapeutics Inc. (GANX) Stock Exhibits Volatility Following Announcement of Topline Data from Clinical Studies

    Gain Therapeutics Inc. (GANX) stock prices were up by 20.13% as of the market closing on September 8th 2021. This brought the price per share up to USD$9.49 at the end of the trading day. Subsequent premarket fluctuations saw the stock dip by 7.80%, bringing it down to USD$8.75.

    GANX Stock’s Positive Topline Data

    September 8th 2021 saw GANX stock announce the topline data from its clinical study of GT-02287 and GT-02329. The study is designed to evaluate the two lead Structurally Targeted Allosteric Regulators (STARs) compounds. These compounds are hoped to treat Gaucher and GBA 1 Parkinson’s Disease. The results indicated positive effects on all tested phenotypes. The biotechnology company is focused on identifying and optimizing allosteric binding sites that have never before been targeted in neurodegenerative diseases and lysosomal storage disorders.

    Parkinson’s Disease Treatment

    GANX stock’s lab is using human induced pluripotent stem cells to test the efficacy of the two lead STAR chaperones. These chaperones were developed by Gain Therapeutics and the stem cells were derived from patients with GD and GBA-associated Parkinson’s Disease. The studies in iPSC-derived cortical and dopaminergic neurons from neuronpathic Gaucher Disease patients demonstrate the potential of the compounds. This potential is in regard to an increase in the levels of GCase protein, its transport to the lysome, and its enzymatic activity. The two lead STAR chaperones have also been shown to decrease the levels of α-synuclein-p129 in dopaminergic neurons. This demonstrates the potential to treat GBA1-associated Parkinson’s Disease.

    Scope of Topline Data

    The data collected is highly promising, as it continues to consolidate the potential of GT-02287 and GT-02329. This development expands the collection of evidence that supports the company’s Site-Directed Enzyme Enhancement Therapy (SEE-Tx) drug discovery platform. The results of the study are being fully evaluated in the interest of presented a complete data set. This data set will be presented at the upcoming Michael J. Fox Foundation’s webinar. Furthermore, GANX stock anticipates initiating IND-enabling studies for Gaucher and Parkinson’s Disease in the fourth quarter of the current fiscal year.

    Future Outlook for GANX Stock

    GANX stock reported a promising quarter, consolidated by the success of its topline data for GT-02287 and GT-02329. The company is poised to capitalize on the opportunities presented to it as it spearheads the commercialization and proliferation of its treatments. Current and potential investors are hopeful that management will be able to usher in significant and sustained increases in shareholder value over the long term.

  • Humanigen Inc. (HGEN) Stock Plummets Following FDA’s Declining of EUA for Lenzilumab

    Humanigen Inc. (HGEN) Stock Plummets Following FDA’s Declining of EUA for Lenzilumab

    Humanigen Inc. (HGEN) stock prices were down by 3.94% as of the market closing on September 8th, 2021. This brought the price per share down to USD$15.11 at the end of the trading day. Subsequent premarket fluctuations saw the stock plummet by 50.96%, bringing it down to USD$7.41.

    EUA for Lenzilumab

    HGEN stock reported on September 9th, 2021 that the U.S Food and Drug Administration declined the company’s request for EUA. The emergency use authorization submission was for the company’s proprietary lenzilumab. The treatment was hoped to address the demographic of newly hospitalized Covid-19 patients. The clinical-stage biopharmaceutical company has concentrated its efforts to prevent and treat cytokine storm, an immune hyper-response. The FDA declined the EUA submission on the basis of not being able to conclude that the pros of the treatment would outweigh known and potential risks.

    HGEN Stock Working with FDA

    The United States Food and Drug Administration has committed to collaborating with HGEN stock. This partnership will serve to facilitate the development of lenzilumab. HGEN stock has been invited to submit additional data as it becomes available. The company is looking forward to NIH’s ACTIV-5/BET-B study, which is expected to provide further data. This data is expected to support a new emergency use authorization request. The company continues to allocate resources towards completing regulatory processes for lenzilumab. This is hoped to lead to Marketing Authorization for the company’s treatment for patients in the U.K and abroad.

    Working Towards EUA Approval

    Lenzilumab is a first-in-class antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). Preclinical model projections indicate GM-CSF’s capacity as an upstream regulator of various inflammatory cytokines and chemokines involved in the cytokine storm. Investigations following the onset of the pandemic indicated high levels of GM-CSF secreting T cells to be linked to disease severity and ICU admission. HGEN stock’s Phase 3 LIVE-AIR study suggests early intervention with lenzilumab has the potential to prevent consequence of a full blown cytokine storm in hospitalized Covid-19 patients. The company has submitted lenzilumab to Medicines and Health Regulatory Agency in the UK. This submissions is for a rolling review towards potential Marketing Authorization.

    Future Outlook for HGEN Stock

    The FDA’s declining of EUA for lenzilumab has been a major blow to the company. HGEN stock is poised to leverage its resources towards remedying the situation. Investors are hopeful that management will be able to facilitate the commercialization and proliferation of its flagship treatment. This is hoped to result in significant and sustained increases in shareholder value.

  • AGM industries Inc. (ABM) Stock Exhibits Minor Volatility Following Disclosure of Q3 2021 Financial Reports

    AGM industries Inc. (ABM) Stock Exhibits Minor Volatility Following Disclosure of Q3 2021 Financial Reports

    AGM Industries Inc. (ABM) stock prices were up by 0.064% as of the market closing on September 8th, 2021. This brought the price per share up to USD$47.25 at the end of the trading day. Subsequent premarket fluctuations saw the stock dip by 4.76%, bringing it down to USD$45.00.

    ABM Stock’s Revenue Reports

    The third quarter of fiscal 2021 saw ABM stock report USD$1.54 million in revenue. This is a 10.7% increase from the numbers, as compared to the prior-year quarter. Gradual re-occupancy of offices and the return of fans to sports venues drove Business and Industry revenue. Aviation revenue was up by more than 50%, with the operating margin for the segment surpassing pre-pandemic levels. This is a result of an increase in domestic air travel, as well as a favorable mix of the airport business. Technical Solution’s revenues and operating income were up by double digits. The increase reflected effective execution on an increasing backlog of energy-efficient projects, as well as greater access to client sites. Demand for disinfection-related services remained elevated, resulting in revenue growth and increased operating profitability.

    GAAP Net Loss

    ABM stock reported a GAAP net loss from continuing operations in the amount of USD$13.7 million. This represented a GAAP net loss of USD$0.20 per diluted share. These figures include a USD$1.24 per share reserve to resolve outstanding litigation. GAAP net income from continuing operations came out to USD$56 million in the prior-year quarter.

    Q3 2021 Improvements

    Results from continuing operations for the third quarter of fiscal 2021 reflected an increase in higher-margin virus protection services. On both a GAAP and adjusted basis, the increase was driven by clients’ continued incorporation of disinfection into their operations. Quarterly results also benefitted from efficient management of direct labor and lower bad debt expense. The 2021 quarter also had one less workday as compared to the prior-year quarter. Higher corporate expenses contributed to the offsetting of these gains. These expenses primarily reflected planned investments in information technology. Higher personnel costs also offset the favorable factors from the prior year. This was a result of furlough and related cost-saving actions taken at the onset of the global pandemic.

    Future Outlook for ABM Stock

    The company reported a strong quarter, as evidenced by the strength of its financial reports for Q3 2021. ABM stock is poised to capitalize on the opportunities afforded to it as a result of the momentum it generated over the quarter. Current and potential investors are confident that management will be able to leverage the resources at its disposal. This is hoped to facilitate significant and sustained increases in shareholder value.

  • Candel Therapeutics Inc. (CADL) Stock Surges Following Massive Success of Financial Reports for Q2 2021

    Candel Therapeutics Inc. (CADL) Stock Surges Following Massive Success of Financial Reports for Q2 2021

    Candel Therapeutics Inc. (CADL) stock prices surged by 19.38% some time after market trading commenced on September 9th 2021. This brought the price per share up to USD$11.89 early on in the trading day.

    CADL Stock’s CAN-2409 Study

    April 13th 2021 saw CADL stock announce the formation of its new Research Advisory Board. April 22nd marked the announcement of the completion of enrollment in the company’s phase 1 clinical trial. The trial enrolled patients with new diagnosed high-grade glioma. It was designed to evaluate the safety and efficacy of CAN-2409 in combination with Opdivo (nivolumab) and standard of care radiation therapy. Patients with a methylated MGMT promotor were also administered temozolomide.

    Solid Liquidity Position

    CADL stock reported a stellar liquidity position at the end of the second quarter of fiscal 2021. Cash and cash equivalents came out to USD$24.3 million. This is comparable to the USD$35.1 million reported as of December 31st 2020. August 2021 saw the company complete its initial public offering. The offering saw the issuance of 9,887,994 shares of common stock, with each stock being priced at USD$8.00 per share. Net proceeds generated from the offering came out to USD$71.5 million after the deduction of expenses related to the offering. As per current projections, the company expects its liquidity position to fund its operations through to the second quarter of 2023.

    R&D Expense Reports

    Research and development costs for the second quarter of fiscal 2021 came out to USD$3.3 million. The first half of fiscal 2021 saw the company report R&D expenses in the amount of USD$6 million. This is comparable to the USD$1.8 million reported for Q2 2020 and USD$3.4 million for H1 2020. The year over year increases were largely driven by increased personnel-related costs. The additional headcount was required to support the ongoing clinical trials for product candidates. Further consolidating the yearly difference were increased clinical development costs.

    Future Outlook for CADL Stock

    CADL stock reported a promising quarter, as evidenced by the strength of its financial reports for Q2 2021. The company is keen to capitalize on the opportunities afforded to it as a result of the momentum generated over the course of the quarter. Current and potential investors are hopeful that management will be able to leverage the resources at their disposal. This is hoped to usher in significant and sustained increases in shareholder value over the long term.